John Hamill - Mar 28, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role: SrVP/CFO/Prin Fin & Acct Ofcr
Signature: /s/ John Hamill
Stock symbol: APRE
Transactions as of: Mar 28, 2024
Transactions value $: $0
Form type: 4
Date filed: 3/28/2024, 05:59 PM
Previous filing: Mar 14, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APRE	Common Stock	Award	$0	+3.37K	+21.71%	$0.00	18.9K	Mar 28, 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APRE	Stock Options (Right to Buy)	Award	$0	+13.5K		$0.00	13.5K	Mar 28, 2024	Common Stock	13.5K	$6.69	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2	Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.